

LEGNID

EU opportunities, Italian success

A revolutionary diagnostic device
for lung cancer

1 Dicembre 2016 ore 10:00

Diatech Pharmacogenetics
Via Ignazio Silone 1b, Jesi (AN)

diatech
pharmacogenetics



The main scope of **LEONID project** is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment.

The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK.

The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility.

The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers.

For **Diatech Pharmacogenetics**, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company's approach of potential European distributors. GenetiCLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests' results and can provide its new software through Diatech PGx or directly.

LEGNID

EU opportunities, Italian success

A revolutionary diagnostic device
for lung cancer



PROGRAMMA

Ore 10:00

Welcome to Diatech!

Visita dell'azienda Diatech Pharmacogenetics
Hall, 2° piano

Ore 11:00

Evento di presentazione dei risultati del progetto LEONID

Sala convegni, 2° piano

Saluti di benvenuto

Fabio Biondi

Presidente Diatech Pharmacogenetics

Luca Ceriscioli

Presidente Regione Marche

Mariangela Siler

DG ricerca e innovazione in sanità, Ministero della Salute

Ore 11:30

Le politiche e i bandi regionali in campo sanitario

Manuela Bora

Assessora alle Attività Produttive della Regione Marche

Ore 11:50

Le imprese italiane nei programmi europei e nazionali per la R&I

Nicoletta Amodio

Dirigente Ricerca e Innovazione, Confindustria

Ore 12:10

La storia e i risultati del progetto LEONID

Maura Menghi

Direttore Scientifico Diatech Pharmacogenetics

Ore 12:30

Studio clinico LEONID: presentazione dei risultati preliminari

Paola Ulivi

Settore Biomarcatori e Medicina Personalizzata-
Diagnostica molecolare III livello, Istituto Scientifico
Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS
Meldola

Ore 12:45

Myriapod® Lung Fusion Genes nella pratica clinica

Gabriella Fontanini

Dipartimento di Patologia Medica Molecolare e di Area
Critica, Università di Pisa

Ore 13:00

Networking lunch

Spazio adiacente Sala Convegni, 2° piano

LEGNID



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No° 673953

diatech
pharmacogenetics

Diatech Pharmacogenetics srl

Via Ignazio Silone 1b - 60035 Jesi (An) Italy

Phone +39 0731 213 243

marketing@diatechpgx.com

www.diatechpharmacogenetics.com